Search CRSP
CRISPR Therapeutics AG
Nasdaq · CIK 1674416
Last close55.43
Daily change-0.01 (-0.02%)
10 Years gain+293.40%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CRSP · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
54.8Momentum
100.0Acceleration
60.0Confidence
82.0Annual Revenue11
Quarterly Revenue42
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality8.6 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics1.2 / 10
Forward Indicators5.0 / 5
Signals
Operating leverageOperating margin improved by 17584.9689 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 12.3057%.
ROIC declining · MEDIUMROIC declined by 100.7633 percentage points.
Key Metrics
Revenue Growth TTM439.39%OK
Revenue CAGR 3Y43.09%OK
Gross Margin100%OK
Operating Margin-4,537.26%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-542.14%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y12.31%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $3.51M | $3.51M | -$664.57M | -$345.01M | -$345.93M | 100% | -18,933.65% | -9,855.5% | n/a | 89.93M |
| 2025 FY Dec 31, 2024 | $37.31M | $37.31M | -$466.57M | -$142.77M | -$144.68M | 100% | -1,250.38% | -387.72% | -339.14% | 84.36M |
| 2025 FY Dec 31, 2023 | $371.21M | $371.21M | -$222.54M | -$260.38M | -$269.85M | 100% | -59.95% | -72.69% | -141.05% | 79.22M |
| 2024 FY Dec 31, 2022 | $1.20M | $1.20M | -$673.16M | -$495.74M | -$532.93M | 100% | -56,190.4% | -44,484.89% | -1,321.37% | 77.75M |
| 2023 FY Dec 31, 2021 | $914.96M | $914.96M | $373.53M | $538.97M | $457.27M | 100% | 40.82% | 49.98% | n/a | 80.39M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $13.42M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-330672, 0001193125-25-273337 |
| Revenue Growth TTM | 439.39% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-330672, 0001193125-25-273337 |
| Revenue CAGR 3Y | 43.09% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-048957 |
| Revenue CAGR 5Y | 37.31% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-048957 |
| Gross Profit CAGR 3Y | 43.09% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-048957 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-330672, 0001193125-25-273337 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001193125-26-330672, 0001193125-25-273337 |
| Operating Margin | -4,537.26% | Operating Income / Revenue | OK | 0001193125-26-330672, 0001193125-25-273337 |
| ROIC | -542.14% | NOPAT / Average Invested Capital | OK | 0001193125-26-330672, 0001193125-25-273337 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-330672 |
| Current Ratio | 17.85x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 4.03x | (Cash + Short-term Investments) / Total Debt | OK | 0001193125-26-330672 |
| Revenue per Diluted Share | $0.14 | Revenue / Diluted Shares | OK | 0001193125-26-330672, 0001193125-25-273337 |